What are the channels for purchasing mivamutide injection and how to choose?

Mifamurtide injection (Mifamurtide) is an immunomodulatory adjuvant treatment drug specially used for patients with osteosarcoma (osteosarcoma), especially for patients with high-risk osteosarcoma who have undergone surgical resection. As an immune activator, mivamutide improves disease-free survival and overall prognosis of patients by enhancing the anti-tumor activity of the monocyte-macrophage system. Its indications mainly include postoperative adjuvant treatment for children and adolescents with osteosarcoma, aiming to reduce the risk of tumor recurrence and metastasis.

At present, mivamutin injection has not been officially launched in mainland China, and patients cannot obtain the drug through regular hospitals or pharmacies in China. Legal channels mainly rely on overseas imports, especially the European, American and Japanese markets. Drug manufacturers usually provide services to patients around the world through specific international drug supply chains. If patients or their families need medicines, it is recommended that they make formal purchases through qualified overseas medical service institutions or international drug procurement platforms to ensure that the sources of medicines are legal and meet quality standards.

When choosing purchase channels, priority should be given to the registration status of the product and the reputation of the supplier to avoid potential drug safety risks caused by informal channels. It is recommended that patients cooperate with oncologists for reasonable treatment planning and drug management, and avoid purchasing and using uncertified drugs on their own. In addition, overseas procurement may involve higher costs and transportation time. Patients and their families should plan in advance and fully understand the relevant processes to ensure continuity of treatment.

In summary, mivamutin injection is an important auxiliary drug in the treatment of osteosarcoma. It has clear indications and relatively limited purchase channels. It needs to be obtained through formal overseas channels to ensure safety and efficacy.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact